1. Home
  2. LPTX vs FAT Comparison

LPTX vs FAT Comparison

Compare LPTX & FAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPTX
  • FAT
  • Stock Information
  • Founded
  • LPTX 2011
  • FAT 2017
  • Country
  • LPTX United States
  • FAT United States
  • Employees
  • LPTX N/A
  • FAT N/A
  • Industry
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • FAT Restaurants
  • Sector
  • LPTX Health Care
  • FAT Consumer Discretionary
  • Exchange
  • LPTX Nasdaq
  • FAT Nasdaq
  • Market Cap
  • LPTX 117.1M
  • FAT 94.4M
  • IPO Year
  • LPTX N/A
  • FAT 2017
  • Fundamental
  • Price
  • LPTX $2.74
  • FAT $5.28
  • Analyst Decision
  • LPTX Strong Buy
  • FAT
  • Analyst Count
  • LPTX 4
  • FAT 0
  • Target Price
  • LPTX $8.63
  • FAT N/A
  • AVG Volume (30 Days)
  • LPTX 452.0K
  • FAT 20.5K
  • Earning Date
  • LPTX 11-13-2024
  • FAT 10-30-2024
  • Dividend Yield
  • LPTX N/A
  • FAT 10.59%
  • EPS Growth
  • LPTX N/A
  • FAT N/A
  • EPS
  • LPTX N/A
  • FAT N/A
  • Revenue
  • LPTX N/A
  • FAT $606,008,000.00
  • Revenue This Year
  • LPTX N/A
  • FAT $34.73
  • Revenue Next Year
  • LPTX N/A
  • FAT $2.67
  • P/E Ratio
  • LPTX N/A
  • FAT N/A
  • Revenue Growth
  • LPTX N/A
  • FAT 42.38
  • 52 Week Low
  • LPTX $1.55
  • FAT $4.51
  • 52 Week High
  • LPTX $5.00
  • FAT $9.48
  • Technical
  • Relative Strength Index (RSI)
  • LPTX 39.77
  • FAT 49.33
  • Support Level
  • LPTX $3.40
  • FAT $5.22
  • Resistance Level
  • LPTX $3.61
  • FAT $5.75
  • Average True Range (ATR)
  • LPTX 0.40
  • FAT 0.26
  • MACD
  • LPTX -0.13
  • FAT -0.01
  • Stochastic Oscillator
  • LPTX 1.91
  • FAT 35.62

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

About FAT FAT Brands Inc.

FAT Brands Inc is a multi-brand restaurant franchising company. It develops, markets, acquires and manages quick service, fast casual, casual dining, and polished casual dining restaurant concepts around the world. The company operates as a franchisor of restaurants, where the company generally does not own or operate the restaurant locations but rather generates revenue by charging franchisees an initial franchise fee as well as ongoing royalties. For some of the company's brands, it also directly owns and operates restaurant locations. Its brands include Round Table Pizza, Fatburger, Johnny Rockets, Twin Peaks, and Elevation Burger among others. Geographically, the majority of the revenue for the company is generated from the United States and the rest from other countries.

Share on Social Networks: